Cargando…

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment

Cyclin-dependent kinase 12 (CDK12) is a serine/threonine kinase involved in the regulation of RNA polymerase II and in the transcription of a subset of genes involved in the DNA damage response. CDK12 is one of the most mutated genes in ovarian carcinoma. These mutations result in loss-of-function a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chilà, Rosaria, Chiappa, Michela, Guffanti, Federica, Panini, Nicolò, Conconi, Donatella, Rinaldi, Andrea, Cascione, Luciano, Bertoni, Francesco, Fratelli, Maddalena, Damia, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328802/ https://www.ncbi.nlm.nih.gov/pubmed/35912188 http://dx.doi.org/10.3389/fonc.2022.903536

Ejemplares similares

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
por: Ricci, Francesca, et al.
Publicado: (2016)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020)

Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment
por: Kim, Jeewon, et al.
Publicado: (2017)

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
por: Gaudio, Eugenio, et al.
Publicado: (2016)

A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer
por: Tian, Chenchen, et al.
Publicado: (2022)

PARP1 Gene Knock-Out Increases Resistance to Retinal Degeneration without Affecting Retinal Function
por: Sahaboglu, Ayse, et al.
Publicado: (2010)

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
por: Aziz, Diar, et al.
Publicado: (2021)

Analyzing structure–function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells
por: Rank, Lisa, et al.
Publicado: (2016)

MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance
por: Wang, Juan, et al.
Publicado: (2017)

PARty promoters: Hormone-dependent gene regulation requires CDK2 activation of PARP1
por: Wright, Roni H.G., et al.
Publicado: (2012)

The New Frontiers in Neurodegenerative Diseases Treatment: Liposomal-Based Strategies
por: Cascione, Mariafrancesca, et al.
Publicado: (2020)

Inorganic Nanomaterials versus Polymer-Based Nanoparticles for Overcoming Neurodegeneration
por: Martano, Simona, et al.
Publicado: (2022)

Isolation and characterization of two newly established thymoma PDXs from two relapses of the same patient: a new tool to investigate thymic malignancies
por: Mendogni, Paolo, et al.
Publicado: (2022)

Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential
por: Conconi, Donatella, et al.
Publicado: (2017)

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
por: Ning, Jian-Fang, et al.
Publicado: (2019)

Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2018)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy
por: Giambra, Martina, et al.
Publicado: (2023)

Knocking down CDK4 mediates the elevation of let-7c suppressing cell growth in nasopharyngeal carcinoma
por: Liu, Zhen, et al.
Publicado: (2014)

For New Neurons in an Old Brain, cdk5 Shows the Way
por: Robinson, Richard
Publicado: (2008)

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer
por: Guffanti, F., et al.
Publicado: (2016)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies
por: Nerone, Marta, et al.
Publicado: (2023)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin
por: Endo, Shino, et al.
Publicado: (2021)

The degree of altriciality and performance in a cognitive task show correlated evolution
por: Chiappa, Pilar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jbpm82493dkto75r6g52nqjg29